Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.

Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK.

Cancer Biol Ther. 2009 Aug;8(16):1596-603. Epub 2009 Aug 13.

2.

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK.

Mol Cancer Ther. 2010 Apr;9(4):985-95. doi: 10.1158/1535-7163.MCT-09-0967. Epub 2010 Apr 6.

3.

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK.

Mol Cancer Ther. 2015 Dec;14(12):2677-86. doi: 10.1158/1535-7163.MCT-14-0630. Epub 2015 Oct 29.

4.

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.

Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK.

Cancer Res. 2007 Jan 1;67(1):281-8.

5.

Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.

Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, Auzenne EJ, Lopez-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AK.

Clin Cancer Res. 2012 Aug 1;18(15):4114-21. doi: 10.1158/1078-0432.CCR-11-3250. Epub 2012 Jun 12.

6.

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, Kerbel RS.

Mol Cancer Ther. 2010 Apr;9(4):996-1006. doi: 10.1158/1535-7163.MCT-09-0960. Epub 2010 Apr 6.

7.

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.

Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS.

Oncotarget. 2015 Dec 15;6(40):42396-410. doi: 10.18632/oncotarget.6377.

8.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

PMID:
17077358
9.

Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

Kumar S, Mokhtari RB, Sheikh R, Wu B, Zhang L, Xu P, Man S, Oliveira ID, Yeger H, Kerbel RS, Baruchel S.

Clin Cancer Res. 2011 Sep 1;17(17):5656-67. doi: 10.1158/1078-0432.CCR-11-0078. Epub 2011 Jul 25.

10.

Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

Cruz-Muñoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, Collins C, Banville M, O'Connor-McCourt MD, Kerbel RS.

Angiogenesis. 2014 Jul;17(3):661-73. doi: 10.1007/s10456-014-9422-9. Epub 2014 Feb 26.

11.

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Feb;9(3):176-82. Epub 2010 Feb 16.

12.

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.

Patten SG, Adamcic U, Lacombe K, Minhas K, Skowronski K, Coomber BL.

BMC Cancer. 2010 Dec 15;10:683. doi: 10.1186/1471-2407-10-683.

13.

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK.

Clin Cancer Res. 2007 Jun 1;13(11):3423-30.

14.

Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer.

Jiang H, Feng Y.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:405-12.

PMID:
16515634
15.

Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.

Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, Ohmichi M.

Cancer Biol Ther. 2010 Dec 1;10(11):1137-46. doi: 10.4161/cbt.10.11.13443. Epub 2010 Dec 1.

16.

Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.

Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, Stolar C, Middlesworth W, Yamashiro DJ, Kandel JJ.

J Pediatr Surg. 2001 Aug;36(8):1177-81.

PMID:
11479851
18.

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK.

Cancer Biol Ther. 2009 Dec;8(23):2263-72. Epub 2009 Dec 19.

19.

Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.

Pourgholami MH, Cai ZY, Badar S, Wangoo K, Poruchynsky MS, Morris DL.

BMC Cancer. 2010 Apr 15;10:143. doi: 10.1186/1471-2407-10-143.

20.

Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?

Shen FZ, Wang J, Liang J, Mu K, Hou JY, Wang YT.

Int J Exp Pathol. 2010 Feb;91(1):10-6. doi: 10.1111/j.1365-2613.2009.00684.x.

Supplemental Content

Support Center